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In the era of next-generation sequencing, there are significant challenges to harnessing cancer
genome information to develop novel therapies. Key research thrusts in both academia and
industry will speed this transition, and lessons learned for cancer will shape the process for genetic
contributions to the therapy of disease more broadly.Introduction
Breakthrough advances in the treatment of
medical illness require the elucidation of
the pathogenic mechanisms initiating and
driving disease states. Cancer is largely
a disease of the genome, and through
recent technological advances, we are
now able to separate the ‘‘diseased’’
cancer genome from the normal genome.
Asaconsequence, thenextdecadeshould
see dissection of disease-relevant somatic
mutations and the completion of the
‘‘pathogenetic’’ landscape of cancer,
paving the way for further therapeutic
development.
The discovery of key pathogenetic
cancer alterations has already trans-
formed the treatment of specific cancer
types. The introduction of all-trans retinoic
acid to the treatment of acute promyelo-
cytic leukemia harboring translocations
into the RARa gene has led to curative
responses in the majority of patients
(Huang et al., 1988). Treatment of chronic
myelogenous leukemia, bearing the BCR-
ABL fusion gene,with imatinib, an inhibitor
of the Abelson kinase, has led to a stag-
gering 80% decline in disease mortality
(Figure 1). More recently, inhibitors target-
ing EGFRmutations in adenocarcinomaof
the lung, BRAF mutations in melanoma,
and ALK translocations in lung cancer
highlight the potential to alter the course
of previously untreatable disease (re-
viewed in Haber et al., 2011). These
encouraging results strongly suggest that
the next step toward the goal of curing
cancer is to more fully exploit this
genetic-therapeutic strategy.
Though access to ever-increasing
amounts of sequence information holds26 Cell 147, September 30, 2011 ª2011 Elsegreat promise, there are at least five
significant barriers to this goal. First, we
do not yet have a complete picture of
the genetic alterations comprising the
disordered cancer genome. Second, the
discovery of specific mutations that lead
to cancer, so called ‘‘driver’’ mutations,
is too often accompanied by an inability
to create a relevant therapeutic molecule.
In other words, there is a ‘‘druggability
gap.’’ Third, most cancers, particularly
those that are late stage, are genetically
heterogeneous or capable of rapid
genetic evolution. Either scenario can
lead to the rapid emergence of thera-
peutic resistance. Fourth, as a corollary
to the problem of resistance, combination
therapy will be required to achieve thera-
peutic cure or long-lasting disease
control. Finally, the ability to make more
definitive predictions about clinical thera-
peutic outcome is severely limited by the
lack of robust preclinical disease models.
‘‘Completing’’ the Human Cancer
Genome
The daunting complexity of the human
cancer genome is amply illustrated by
the emerging fully characterized cancer
genomes. For example, a recent study
looking at prostate cancer identified
substantial variation between the patient
tumors (Figure 2) (Berger et al., 2011).
This complexity appears bothas thediver-
sity of genetic alterations across many
cancer types and samples and the
complexity within single tumors, in which
the background mutation frequency
(‘‘carrier’’ mutations) often exceeds the
frequency of ‘‘driver’’ mutations. Thus, in
order to distinguish the critical geneticvier Inc.alterations of therapeutic interest, repeti-
tive mutations or repetitively mutated
genes across many samples from indi-
vidual tumor types must be identified and
correlated with disease in a relevant
manner.
One can envision a broader goal
requiring larger sample sets whereby we
would define not only the cancer gene
alterations, but also the cancer gene inter-
actions. As examples, early efforts to
describe the glioblastoma genome identi-
fied three core interacting genetic path-
ways in this disease (The Cancer Genome
Atlas Research Network, 2008), whereas
low-frequency single-gene mutations ap-
pear to, in aggregate, target the NFKB
pathway in myeloma (Chapman et al.,
2011). Therefore, the vision of ‘‘complete-
ness’’ is to characterize cancer genomes
at a sufficient scale so that genetic inter-
actions can be used to directly define
the key functional cancer pathways and
potentially the therapeutic targets.
To this end, the goal should be to
describe three interaction attributes
beyond single-gene mutation frequency,
specifically: (1) to identify those genetic
alterations that co-occur at a greater
frequency than by chance alone and are
hence cooperative, (2) to identify those
genes in which alterations anticorrelate
and thus provide a similar function or
where co-mutation is incompatible with
cancer cell progression, and (3) to identify
genes whose coding sequence is notable
for the absence of backgroundmutations.
In this latter case, the absence of back-
ground loss-of-function mutations could
potentially define genes whose func-
tion is absolutely required for cancer cell
Figure 1. CML Mortality Has Declined in the United States, and the
Annual Incidence Is Unchanged
Shown are the estimated US-based CML incidence and mortality rates for the
years 1997, 1998, and 2000–2011. These data were abstracted from the
annual cancer statistics publications published by CA: A Cancer Journal for
Clinicians’ in the years 1997, 1998, and 2000–2011 (Siegel et al., 2011).survival. This so-called class
of ‘‘never-mutated’’ genes
will likely be conditioned by
driver genetic events and
could be an important new
class of ‘‘conditional lethality’’
genes particularly relevant
to therapeutic development.
Advances in sequencing
technology have created the
opportunity to achieve these
goals; however, high-priority
efforts must now be made to
address the remaining rate-
limiting steps of tumor sample
acquisition, data handling,
and data analysis.
From Genetics to
Therapy: Bridging the
Druggability Gap
The identification of protein
kinases, activated by somatic
mutation, has led the recent
wave of therapeutic break-
throughs outlined above. In
sharp contrast is the realiza-
tion that most of the known
critical oncogenes and tumorsuppressors remain beyond the reach
of current therapeutic modalities. Se-
quencing projects have reaffirmed TP53
as the most commonly mutated tumor
suppressor gene and the RAS oncogenes
(K-RAS and N-RAS) as key drivers of
a variety of devastating cancers. Yet, the
elucidation of p53 and RAS biology has
not been coupled with major revolutions
in therapeutics based on these genetic
alterations. Similarly, the discovery of
key oncogenic transcription factors,
including MYC, NMYC, ERG, and others,
has not been paralleled by the develop-
ment of transcription factor inhibitors. To
address this druggabilty gap, it is first
necessary that we challenge the notion
of what is ‘‘undruggable’’ so that drug
targets are not rejected outright based
on prior assumptions (or past failures).
Similar prejudices led to the premature
conclusions that kinases and other ATP-
utilizing enzymes were themselves un-
druggable. The development of drugs dis-
rupting protein-protein interactions (PPI)
between IAPs and SMAC (Sun et al.,
2004), between p53 and HDM2 (Vassilev
et al., 2004), and, most notably, along
the remarkably extended interfacebetween BH3-containing proteins and
BCL2 family members belie the notion
that such PPI targets are inherently intrac-
table (Oltersdorf et al., 2005).
Further broadening of the scope of
druggable targets can be achieved
through a number of parallel mechanisms.
In the arena of ‘‘typical’’ synthetic low-
molecular weight molecules, we will
benefit from increases in diversity and
scale of available small-molecule li-
braries. In academia, renewed interest in
direct participation in drug discovery
has enabled establishment of modest-
scale low-molecular weight screening
facilities. Such efforts may focus on
phenotype-oriented drug discovery, and
hopefully breakthroughs against difficult
targets will follow. But centers must be
bolstered with robust medicinal chemistry
resources, or it will become difficult to
make advances beyond the relatively
weak nonspecific inhibitors typically iden-
tified through screening. The most chal-
lenging drug discovery projects (e.g.,
PPIs) typically require structure-based
guidance (X-ray and NMR) and an invest-
ment in biophysical analysis platforms.
Indeed, in tackling challenging drugCell 147, September 3targets, it is likely that these
resources will be of more
value than the screening plat-
forms themselves.
In industry, time-depen-
dent pressure to delivermole-
cules ready for clinical trials
drives early-stage drug dis-
covery efforts focused on
tractable targets, including
those with often tenuous links
to disease pathogenesis over
those focused on difficult
targets with incontrovertible
disease linkage. Perversely,
this can reward a scenario of
costly late-clinical failure
based on the invalidation of
the therapeutic hypothesis
over a scenario of early-re-
search failure based on drug-
gability. Notably, the current
biotechnology venture-based
funding model suffers from
the same short-term reward
structure. Somehow, a pro-
portion of the biopharma-
ceutical drug discovery re-
source must be dedicatedover the longer term to the discovery of
compounds that break new ground
against the most challenging of targets.
To expand these efforts on the smallmole-
cule front for particular targets, we need
research funding mechanisms in acade-
mia or industry that are compatible with
the 5–10 year timescale required for tack-
ling difficult drug discovery problems.
Alternative therapeutic modalities,
including therapeutic siRNA, intracellular
peptide therapies, and gene therapy,
hold promise for a broad attack on the
druggability gap but are all beset by a
common issue: difficult drug delivery.
The challenge to the delivery of thera-
peutic siRNA remains essentially un-
changed from that faced by antisense
oligonucleotides. The molecules are large
(>10,000MW) and highly charged,making
distribution across biological membranes
problematic (Shim and Kwon, 2010). To
realize the promises for these novel thera-
peutic classes, a renewed focus on
systematic and robust approaches to the
delivery problem is warranted.
In the short-term, certain key cancer
genesare likely to remain relativelydifficult
to drug. This is a notable problem for the0, 2011 ª2011 Elsevier Inc. 27
Figure 2. The Chromosomal Rearrangements Found in Seven Prostate Cancer Genomes
Copy number alterations are represented by the colors of the chromosome segments depicted along the inner ring (red, copy gain; blue, copy loss). Intra-
chromosomal rearrangements and interchromosomal translocations are shownwith green and purple lines, respectively Reprinted by permission fromMacmillan
Publishers Ltd: Nature 470, 214–220, copyright 2011.tumor suppressor genes, in which the
gene product is often completely absent.
Here, the hope is to exploit the concept
of ‘‘synthetic lethality’’ or ‘‘conditional
lethality’’ in order to define key therapeutic
targets whose requirement for themainte-
nance of the cancer state is conditioned
by a specific genetic event (Kaelin, 2005).
Such conditional lethality nodes can be
conceived of as existing within a pathway
downstream of an oncogene or tumor
suppressor or in a parallel pathway. In the
case of downstream conditional lethality,
preclinical and clinical proof of concept
has been obtained from the inhibition of
the SMO receptor downstream of tumor
suppressor mutations in the PTCH gene
(Von Hoff et al., 2009), from the inhibition
of mTORC1 downstream of germline
mutations in the TSC genes (Krueger
et al., 2010), and from the inhibition of
MEK downstream of mutant oncogenic
BRAF in melanoma (Solit et al., 2006). In
the case of parallel pathway conditional
lethality, clinical proof of concept has
been obtained from the inhibition of
PARP1 in the context of BRCA1 loss-of-28 Cell 147, September 30, 2011 ª2011 Elsefunction mutations in breast cancer
(Farmer et al., 2005; Fong et al., 2009). In
each case, the key finding is that mutant-
bearing tumors are far more susceptible
to the relevant inhibitor than either nonmu-
tant tumors or the normal host tissue.
The tools for further discovery of such
conditional lethal nodes are only just
becoming available with improvements
in larger-scale shRNA libraries. However,
the robust realization of such discoveries
remains plagued by the noise inherent in
larger-scale shRNA screens and, in
some cases, the overreliance on screens
in isogenic cell line pairs that can often
lead to cell line-specific hits. In this regard,
the alternative approach of cell line panels
should be considered (Brough et al.,
2011). An investment in the development
of highly validated shRNAs for each
human and murine gene could go a long
way in helping to reduce the notion of
conditional lethality to practical discovery.
The Development of Resistance
The evolutionary nature of cancer and its
mutable genome makes emergent thera-vier Inc.peutic resistance a serious and often un-
nerving problem. No doubt this is a major
hurdle inmoving from therapeutic efficacy
to curative cancer therapy. Though there
has been a notable lack of progress in
defining clinically relevant mechanisms
of resistance to classical cytotoxics,
more rapid progress has been seen in
understanding resistance to genetically
directed targeted therapeutics. In partic-
ular, it is clear that, in the latter case, the
preclinical discovery of resistance mech-
anisms can be directly predictive of the
resistance features seen in patients. A
first example was the elucidation of
mechanisms of resistance to imatinib, in
which the preclinical definition of resis-
tance alleles through a random mutagen-
esis and selection process was, in retro-
spect, highly correlated with resistance
alleles uncovered in patient samples
(Azam et al., 2003; Shah et al., 2002).
Similarly, clinically relevant mechanisms
of resistance to EGFR, SMO, and RAF
inhibitors have been uncovered through
a variety of preclinical studies employing
the relevant addicted cell line or animal
models. In parallel, the application of
next-generation sequencing technologies
to the discovery of very low-abundance
pre-existing resistance alleles can allow
confirmation of preclinical discoveries
prior to treatment with relevant inhibitors.
The utility of predictive preclinical resis-
tance studies together with the advent of
deep sequencing raise the possibility that
resistancemechanismscouldbe identified
before the clinical trials of novel therapeu-
ticsbegin. In fact, ideally suchanapproach
would be used to guide improvements in
the first-generation inhibitors during lead
optimization. For example, choicesamong
distinct small-molecule scaffold classes
with alternate binding modes to a target
of interest could be prioritized based on
the frequency andpropensity of resistance
mechanisms and upon which resistance
alleles are detectable in patients prior to
treatment. Presumably, this approach
could accelerate the generation of best-
in-class targeted therapeutics.
The rapid emergence of resistance
during targeted therapy has raised the
specter of an endless chase of resistance
alleles, with ever more specific inhibitors
dealing with an increasing complex spec-
trum of resistance alleles and nongenetic
tumor-adaptive responses. Though this
so-called ‘‘whack-a-mole’’ approach can
lead to the rapid clinical development of
second-generation or third-generation
inhibitors applied in mutation-specific
settings, this will not be the ultimate
strategy for achieving curative therapy.
Rather, defining the emergent principles
of resistance should be used to both (1)
guide improvements to the first-line tar-
geted therapeutics to gain-greater effi-
cacy and (2) elucidate rationale combina-
tions based on the understanding of
escape mechanisms.
What can we say about the principles of
resistance to targeted therapeutics that
are now evident from the study of ABL,
EGFR, KIT, BRAF, and SMO inhibitors?
The common theme is a fairly remarkable
and consistent finding of persistent target
and pathway addiction. Given the
complexity of the cancer genome and
the well-recognized mutability, one might
have imagined that hundreds of distinct
resistance mechanisms would have
emerged in response to any given tar-
geted therapy. Instead, the observation
is that of a consistent pattern of resistancemechanisms, acting in large part to
restore the activity of the original ‘‘addict-
ing’’ pathway. In the case of imatinib-
based treatment of CML, the great
majority of resistance alleles are found in
the ABL kinase domain itself. Based on
these data, ABL inhibitors capable of
both directly suppressing such mutations
and more potently inhibiting the wild-type
kinase have substantially improved the
molecular response rates (Kantarjian
et al., 2010; Saglio et al., 2010). Lung
adenocarcinomas bearing activating
mutations in EGFR show dramatic
response to catalytic EGFR inhibitors but
relapse through direct mutations in the
EGFR kinase domain or through coampli-
fication of MET (Kobayashi et al., 2005;
Pao et al., 2005). In both instances,
a common feature is the restoration of
downstream signaling through phosphoi-
nositide-3 kinase. Based on these data,
second-generation inhibitors, novel
combinations with MET inhibitors and
with PI3K inhibitors, are in development.
Melanomas bearing activating mutations
in BRAF similarly manifest significant
responses to BRAF or MEK inhibitors,
and through heterogeneousmechanisms,
escape is manifest largely by reactivation
of the MEK-ERK cascade. Finally, the
study of resistance to the androgen
receptor pathway inhibitors in prostate
cancer for two decades has focused on
so-called androgen-independent means
of resistance. The recent clinical success
of CYP17 inhibitors (Attard et al., 2008)
and novel AR antagonists (Scher et al.,
2010) has shown, however, that such
‘‘androgen-independent’’ tumors remain
dependent on both AR and AR ligands.
In all, the emerging data from these exam-
ples and others strongly support the
notion that cancers remain highly depen-
dent on these initial dominant oncogenic
pathways and support the elaboration of
improved inhibitors or of ‘‘vertical’’
pathway combinations, where inhibitors
target the same pathway, as at least one
mechanism by which we can improve
the first-line treatment of cancer. Such
combinations are also likely to be effec-
tive in the case of nongenetic or adaptive
resistance mechanisms involving phar-
macologic activation of homeostatic
feedback loops exemplified by the finding
of RTK activation induced by AKT inhibi-
tion (Chandarlapaty et al., 2011).Cell 147, SToward the Discovery and
Development of Curative
Combinations
The majority of curative cancer treatment
regimens involve multidrug combinations.
The emergence of therapeutic resistance
together with the frequent incomplete
response to primary therapy underscores
the importance of developing novel highly
efficacious combinations. Here, we face
substantial challenges in both the re-
search arena and the clinic.
The preclinical discovery of combination
therapies is significantly limited by experi-
mental throughput and by the lack of a
consistent understanding of which mea-
sures of preclinical combination activity
might be predictive of clinical combination
activity. The throughput of combination
profiling in vitro might be solved through
automation; however, animal costs rapidly
become prohibitive if systematic in vivo
combination testing is required. Measures
of combination effect, i.e., the interaction
between two drugs to produce a cellular
outcome, have become increasingly so-
phisticated, yet there is little understanding
of how such improved methods will relate
to the clinic. Efforts to solve this latter
problem are urgently needed.
Theclinical challenge is tomovebeyond
the paradigm that requires the testing of
new agents in combination with existing
standard of care therapies (SOCs). This
incremental strategy ignores the possibili-
ties that novel and existing agents might
be antagonistic and that two novel agents
might be more effective as a combination
without an SOC component. Fortunately,
recognition that this paradigm is inade-
quate has led to early phase II clinical trials
inwhich two novel agents are being tested
in combination prior to the full demonstra-
tion of single-agent activity. Notably, the
observation that the treatment of RAS-
driven tumors may require blockade of
both the PI3K and RAS pathways (Engel-
man et al., 2008) has led to multiple trials
of the ‘‘horizontal’’ combination of AKT or
PI3K inhibitors in combination with MEK
inhibitors. In addition, the ‘‘vertical’’
combination of MEK and RAF inhibitors
is being tried in melanoma (Infante et al.,
2011). If future results of such phase II
trials were truly distinctive, including high
partial and perhaps complete response
rates in relatively unresponsive cancers,
such combinations might be directlyeptember 30, 2011 ª2011 Elsevier Inc. 29
submitted as new drug applications or
might proceed to phase III trials
comparing new combinations against the
accepted standard of care.
The Development of Preclinical
Disease Model Systems
Until recently, preclinical therapeutic pro-
filing was typically confined to the anal-
ysis of a handful of human cancer cell
lines. As such, preclinical testing is con-
ducted on fewer cancer cell lines than
the number of human patients treated in
even exploratory trials. Under such condi-
tions, it is unreasonable to expect either
robust preclinical prediction of the clinical
utility of a candidate therapeutic or the
preclinical discovery and validation of
predictive biomarkers. In simple terms,
the test sets are too small.
Ideally, preclinical models would be of
sufficient robustness and used at suffi-
cient scale so that clinical failure would
be reduced to zero. The complexity of
human cancer makes it unlikely that this
landmark will be attained; nonetheless,
progress toward this goal will be of
unquestionable benefit. The ‘‘required’’
elements of a robust preclinical infrastruc-
ture include molecularly defined model
systems that are directly reflective of their
human counterparts and sufficient model
numbers for one to approach the disease
diversity found in humans. Additionally,
the preservation of stromal-epithelial
interactions, in particular those occurring
through ligand-receptor pairs, along with
the ability to study cancer in the setting
of a functioning immune system, are
vitally important. Lastly, the ability to repli-
cate disease progression and to examine
sufficient intratumoral heterogeneity to
enable the study of resistance are desir-
able for such an infrastructure. It is self-
evident that no single class of preclinical
models will satisfy such requirements.
Moreover, each model system will have
distinct advantages and weaknesses.
Thus, the monolithic view that there is
a single best system for the preclinical
study of therapeutic effect is naive. It is
reasonable, therefore, to take a multi-
pronged approach with the paramount
commonality that each model is related
to human cancer through detailed molec-
ular characterization.
The in vitro study of cancer cell lines is
the only current method for characterizing30 Cell 147, September 30, 2011 ª2011 Elsetherapeutic effect across hundreds of
representative disease models derived
frombona fide human tumors. The artificial
nature of cell culture systems has many
limitations, includinga limit to thespectrum
of human cancer that can be adequately
represented. Nonetheless, cell-autono-
mous growth inhibitory effects can be
robustly studied in many instances. Prior
efforts at systematic profiling, including
the NCI60, were limited by the small
samplesizeand the lackofmolecular char-
acterization. Two efforts to rectify this
deficit have now characterized both the
molecular constituents anddrugsensitivity
of many hundreds of cell lines. The Cancer
Cell Line Encyclopedia project (http://
www.broadinstitute.org/ccle) has com-
pleted the expression profiling, the copy
number analysis, and the exon sequencing
of1600 genes across 949 cell lines avail-
able through commercial sources. The
MGH-Sanger cell line project (Genomics
of Drug Sensitivity in Cancer; http://www.
cancerRxgene.org) has completed the
expression and copy number analysis of
800 cancer cell lines, as well as exon
sequencing of 65 genes commonly mu-
tated in cancer. Full genomic exome
sequencing will be completed by the end
of 2011. These genomic parameters are
being correlated with drug responses to
a panel of 135 anticancer small molecules.
Renewed interest in studying human
tumors without the requirement for
in vitro growth has led to the development
of primary human tumor explants for
propagation in immunocompromised ani-
mals. This approach allows for the devel-
opment of tumormodels characterized by
molecular alterations that appear difficult
to maintain during in vitro growth. In addi-
tion, the function of key developmental
pathways (e.g., the Hedgehog pathway)
are much more likely to be preserved.
Finally, the role of the murine stroma in
supporting the growth of human cancers
can in some instances reflect the human
stromal response. For example, in pan-
creatic cancers, tumor production of
Hedgehog ligands leads to stromal Hh-
pathway activation. In turn, inhibition of
stromal Hh pathway activation by SMO
inhibitors leads to an antitumor response
(Yauch et al., 2008).
Genetically engineered mouse (GEM)
models have the intrinsic advantage of
preserving stromal-to-epithelial interac-vier Inc.tions and a competent immune system.
GEM models are increasingly reflective
of the genetic alterations seen in some
human cancers and likely harbor a high
degree of genetic heterogeneity such
that relevant resistance mechanisms can
be rapidly identified (Buonamici et al.,
2010). These systems remain limited by
the necessity of staging large numbers
of mice for even rudimentary preclinical
trials, and hence transplantable versions
of GEM-derived tumors might provide
a more tractable approach.
Finally, the rapid advances in next-
generation sequencing throughput make
it worth revisiting spontaneous or carcin-
ogen-induced murine cancers, along
with cancers arising in mice with targeted
disruption of DNA repair pathways. Here,
tumors can be collected in large numbers,
and as sequencing costs drop, the full
complement of genetic alterations will be
understood. Such models could then be
accepted or rejected as representatives
of human disease based on a genetic
comparison. This might allow the rapid
development of a large array of geneti-
cally complex transplantable murine
tumors. The growing evidence that pre-
clinical models, when used in robust
numbers and when accurately character-
ized, can be helpful in guiding clinical
development should renew investment in
building these models as a commonly
available resource for wider-spread use.
Implications for Therapeutic
Development in Nononcologic
Diseases
The treatment of the majority of noninfec-
tious medical illness remains largely
based on phenotype. For example, dia-
betic therapy is largely confined to the
lowering of blood glucose, the most
readily measured ‘‘phenotype’’ of this
complex disease. The progress toward
understanding genetic mechanisms of
disease has been notable in those
medical illnesses caused by Mendelian
inherited genetic alterations; however,
progress in defining causally associated
genetic variants has been slower. Limita-
tions to progress in the genetic definition
of medical disease have come in two
forms: (1) the need to more precisely
define distinct subdisease phenotypes
so that genetically diverse diseases are
not admixed and (2) an incomplete ability
to analyze genetic variation, including rare
variants across large sample sets. As is
the case for cancer, we can see the
near-term end of the second roadblock.
And with sufficient attention to the first,
the future discovery of new genetically
defined pathways is likely. The discovery
of complement pathway genetic variants
as the largest attributable factor in the
pathogenesis of macular degeneration is
emblematic of the transformation that
awaits (Edwards et al., 2005; Haines
et al., 2005; Klein et al., 2005).
Following the definition of disease-
causing genetic variants, the same chal-
lenges seen in cancer are likely to arise.
First, the druggability gap will pose
a substantial challenge. As an example,
the identification of genetic alterations in
hemoglobin has not led to a major
advancement in medical therapy of sickle
cell anemia and is reflective of the same
difficulty faced in treating loss-of-function
mutations in tumor suppressor genes.
Though therapeutic resistance through
a hypermutable genome is unlikely to be
a common theme in nononcologicmedical
disease, adaptive resistance through
pathway and endocrine remodeling likely
suggests that combination therapy of
medical illness will be essential.
Lastly, though cancer models are not
ideal, the situation in the medical disease
area is far worse. For most commonly
used therapeutic models (collagen-
induced arthritis, chemical-induced
fibrosis), we have little to no evidence
that they mimic and/or reflect the human
disease. Furthermore, in most cases,
only one model system is used at all.
Again, the likelihood that this testing para-
digm will be predictive of human thera-
peutic success is low. A key challenge in
these areas is to take emerging genetic
data derived from patient-based studies
and create models (likely starting with
GEMs) basedon themost relevant genetic
alterations both alone and in combination.
The completion of the human genome
project provided a roadmap to the even-
tual understanding of disease genomes.
Genetic drivers of disease are now being
elucidated and will allow us to transform
the treatment of human illness. Though
substantial, the hurdles to fully realizing
this transformation can be overcome to
drive the next stages of innovation and
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